Inovio Pharmaceuticals is revolutionizing vaccines for the prevention and treatment of today’s cancers and infectious diseases. The company’s SynCon vaccines are designed to provide universal cross-strain protection against both known and newly emergent unmatched strains of pathogens, such as influenza. Combined with Inovio’s proprietary electroporation delivery, these synthetic vaccines have been shown to generate best-in-class immune responses with a favorable safety profile. For more information, visit the company’s Web site at www.inovio.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: